Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

[1]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[2]  F. Ducray,et al.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2007, Featuring Tumors of the Brain and Other Nervous System , 2011, Journal of the National Cancer Institute.

[4]  K. Franz,et al.  Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  U. Tirelli,et al.  Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. , 2010, Archives of gerontology and geriatrics.

[6]  H. Zentgraf,et al.  Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.

[7]  A. Brandes,et al.  Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma , 2009, Cancer.

[8]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[9]  M. Delorenzi,et al.  Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. , 2008, The Journal of molecular diagnostics : JMD.

[10]  J. Cairncross,et al.  Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme , 2008, Journal of Neuro-Oncology.

[11]  J. Debus,et al.  Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. , 2008, International journal of radiation oncology, biology, physics.

[12]  V. Tombolini,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients , 2008, Journal of Neuro-Oncology.

[13]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[14]  Luc Taillandier,et al.  Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.

[15]  F. Bosman,et al.  An Agarose Matrix Facilitates Sectioning of Tissue Microarray Blocks , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[16]  Lena Damber,et al.  Registrering av primära hjärntumörer mått på nationell vårdkvalitet. Regionala skillnader avslöjade. , 2007 .

[17]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[18]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[19]  K. Hoang-Xuan,et al.  Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations , 2004, Cancer.

[20]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Osoba,et al.  The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires , 1996, Quality of Life Research.

[22]  L. Recht,et al.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas , 2003, Cancer.

[23]  D. Osoba,et al.  Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. , 2000, European journal of cancer.

[24]  D. Osoba,et al.  Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[26]  A. Gregor,et al.  Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma , 1994 .

[27]  J. Cairncross,et al.  A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. , 1994, International journal of radiation oncology, biology, physics.

[28]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[29]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .